The aftermath of the Merck's HIV vaccine trial
<p>Abstract</p> <p>The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-07-01
|
| Series: | Retrovirology |
| Online Access: | http://www.retrovirology.com/content/5/1/56 |
| _version_ | 1811287829849833472 |
|---|---|
| author | Quinto Ileana Fiume Giuseppe Schiavone Marco Iaccino Enrico Scala Giuseppe |
| author_facet | Quinto Ileana Fiume Giuseppe Schiavone Marco Iaccino Enrico Scala Giuseppe |
| author_sort | Quinto Ileana |
| collection | DOAJ |
| description | <p>Abstract</p> <p>The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the Merck's MRKAd5 trivalent candidate vaccine. The vaccine formulation was expected to stimulate a HIV-specific T cell immune response and to either prevent infection, or to reduce the levels of the viral load in vaccinated subjects. Upon the first evaluation of the interim data, the independent Data and Safety Monitoring Board (DSMB) underscored no protection from HIV-1 infection in the vaccine-inoculated volunteers compared with the control group; accordingly, the vaccine trial was stopped. This disappointing outcome warrants a critical analysis of the current vaccine studies and calls for a renewed effort toward a rational design of novel immunogens to be tested in large primate trials.</p> |
| first_indexed | 2024-04-13T03:25:19Z |
| format | Article |
| id | doaj.art-c172340bec2e47e5b3d87fc8d4d91dbc |
| institution | Directory Open Access Journal |
| issn | 1742-4690 |
| language | English |
| last_indexed | 2024-04-13T03:25:19Z |
| publishDate | 2008-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Retrovirology |
| spelling | doaj.art-c172340bec2e47e5b3d87fc8d4d91dbc2022-12-22T03:04:39ZengBMCRetrovirology1742-46902008-07-01515610.1186/1742-4690-5-56The aftermath of the Merck's HIV vaccine trialQuinto IleanaFiume GiuseppeSchiavone MarcoIaccino EnricoScala Giuseppe<p>Abstract</p> <p>The recently released results of the Merck's Phase IIb "test-of concept" vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the Merck's MRKAd5 trivalent candidate vaccine. The vaccine formulation was expected to stimulate a HIV-specific T cell immune response and to either prevent infection, or to reduce the levels of the viral load in vaccinated subjects. Upon the first evaluation of the interim data, the independent Data and Safety Monitoring Board (DSMB) underscored no protection from HIV-1 infection in the vaccine-inoculated volunteers compared with the control group; accordingly, the vaccine trial was stopped. This disappointing outcome warrants a critical analysis of the current vaccine studies and calls for a renewed effort toward a rational design of novel immunogens to be tested in large primate trials.</p>http://www.retrovirology.com/content/5/1/56 |
| spellingShingle | Quinto Ileana Fiume Giuseppe Schiavone Marco Iaccino Enrico Scala Giuseppe The aftermath of the Merck's HIV vaccine trial Retrovirology |
| title | The aftermath of the Merck's HIV vaccine trial |
| title_full | The aftermath of the Merck's HIV vaccine trial |
| title_fullStr | The aftermath of the Merck's HIV vaccine trial |
| title_full_unstemmed | The aftermath of the Merck's HIV vaccine trial |
| title_short | The aftermath of the Merck's HIV vaccine trial |
| title_sort | aftermath of the merck s hiv vaccine trial |
| url | http://www.retrovirology.com/content/5/1/56 |
| work_keys_str_mv | AT quintoileana theaftermathofthemerckshivvaccinetrial AT fiumegiuseppe theaftermathofthemerckshivvaccinetrial AT schiavonemarco theaftermathofthemerckshivvaccinetrial AT iaccinoenrico theaftermathofthemerckshivvaccinetrial AT scalagiuseppe theaftermathofthemerckshivvaccinetrial AT quintoileana aftermathofthemerckshivvaccinetrial AT fiumegiuseppe aftermathofthemerckshivvaccinetrial AT schiavonemarco aftermathofthemerckshivvaccinetrial AT iaccinoenrico aftermathofthemerckshivvaccinetrial AT scalagiuseppe aftermathofthemerckshivvaccinetrial |